Samsrita Labs
- Market cap
- ₹ 30 Cr.
- P/E
- 17.1x
- P/B
- 2.6x
- 52-week range
- 10.15 – 25.27
- ROE
- −69%
- ROCE
- −62.4%
- Dividend yield
- 0%
- Debt / equity
- 0.15
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE
About
Samsrita Labs Limited is an India-based biopharma company. The Company is engaged in activities, such as trading, exports and imports, manufacturing of bulk drugs, research, and development (R&D) through joint ventures or associations or mergers or by its own. It has established platforms in the areas of stem cell research and therapy, new drug discovery, molecular prognosis and diagnostics services, CRO, stem cell focused super specialty hospital, RNA interference technology, and medical devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nanoformulation of cancer drugs, molecular genetics and molecular virology, stem cell, and cord blood banking. Its Molecular Prognosis and Diagnostics services division provides molecular diagnostics and services in the areas of cytogenetics, pharmacogenomics, pathology, radiology, hematology, biochemistry, and microbiology.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Samsrita Labs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17.1 against a typical 21: cheaper than most peers (1st = cheapest).11th of 34
- Share price, 3 months+4.3% against a typical −7.7%.8th of 33
- Size₹ 30.1 Cr. market value against a typical ₹ 83 Cr. (1st = largest).22nd of 34
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2024 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 3 | 0 | 0 |
| Operating Profit | −1 | −0 | −0 | −0 | −0 | −0 | −0 | 0 | −5 | −3 | −0 | −0 |
| OPM % | −216.7% | −3,100% | — | — | — | — | — | — | — | — | −750% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | 0 | −5 | −3 | −0 | −0 |
| Tax % | −14.6% | 0% | −3.2% | 0% | −66.7% | 0% | 0% | — | 0% | 0% | 0% | 0% |
| Net Profit | −0 | −0 | −0 | −0 | −0 | −0 | −0 | 0 | −5 | −3 | −0 | −0 |
| EPS in Rs | −0.28 | −0.18 | −0.2 | −0.13 | −0.01 | −0.03 | −0.01 | 0 | −2 | −1.29 | −0.21 | −0.08 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 15%
- 3 Years
- 0%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −2,814%
- 10 Years
- 5%
- 5 Years
- −18%
- 3 Years
- −12%
- TTM
- —
- 10 Years
- −13%
- 5 Years
- −13%
- 3 Years
- −24%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Samsrita Labs | ₹ 12.00 | ₹ 30 Cr. | 17.1x | 2.6x | −69% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Kalidindi Krishnam Raju
- Executive Chairman of the Board
- K. N. V. Narendra Kumar
- Chief Financial Officer, Executive Director
- M. Gita Usha Rani
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.